Postural and nonmotor disturbances in Parkinson’s disease
Objective: To investigate postural impairments (PI) and their interrelation with non-motor symptoms in patients with Parkinson's disease (PD). Background: PI mechanisms are only partially known.…Presynaptic dopamine depletion predicts late complications and time of progression to advanced disease in patients with early Parkinson’s disease
Objective: To investigate whether the degree of reduced dopamine transporter binding in the striatum is a risk factor for late complications and time of progression…Astroglia exert a neuro-protective role in Parkinson’s disease by reducing oxygen stress through dopamine-induced activation of the pentose-phosphate pathway
Objective: Although dopaminergic neurons themselves take up most of the released dopamine (DA), a part of the DA appears to be taken up by astroglia.…Clinical aspects of postural instability in Parkinson’s disease
Objective: To identify the clinical features of postural instability by PD patients. Background: Postural instability (PI) to maintain body balance while walking. The causes of…Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2
Objective: Using neuromelanin (NM)-MRI, we analyzed whether disease severity and MF is associated with the degree of dopaminergic neuronal degeneration in the substantial nigra compacta…Differences between responders and non-responders of Istradefylline for the wearing off in Parkinson’s disease
Objective: Istradefylline is a selective antagonist of adenosine A2A receptor and was approved first in Japan for Parkinson's disease (PD) patients with by symptoms of…Drp1 inhibition amelioratesα-synuclein-mediated neurodegeneration in rats
Objective: To provide new insights on the relationships occurring between mitochondria physiology and α-synuclein (α-syn) accumulation in an animal model of progressive neurodegeneration. Background: In…Opioid K receptor variant delays the onset of dyskinesias in Parkinson’s disease
Objective: To investigate the genetic factors modulating the timing of the onset of levodopa-induced dyskinesias (LIDs) in Parkinson's disease (PD). Background: Pathophysiological mechanisms underlying LIDs…Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease
Objective: To assess if a microglial modulator, Glatiramer Acetate (GA), can restore loss of striatal dopamine (DA) and behavioral deficits following progressive 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP)…The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease
Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.